Citi Reiterates Buy Rating on Immunovant (IMVT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Immunovant (IMVT) PT Lowered to $33 at BofA Securities
March 19, 2025 2:59 PM EDTBofA Securities analyst Jason Gerberry lowered the price target on Immunovant (NASDAQ: IMVT) to $33.00 (from $38.00) while maintaining a Buy rating.... More
Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies
March 19, 2025 7:45 AM EDTImmunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
We are excited to share positive results from our MG and CIDP studies. While neurologists and patients are very enthusiastic about currently approved FcRn inhibitors, they tell us that they also see a lot of potential for a next-generation FcRn inhibitor that can offer deeper and more... More
